A federal judge has indefinitely blocked a Trump-backed “anti-weaponization” fund, extending what appears to be one of the more consequential early checks on the administration’s effort to steer federal money toward politically charged priorities. While the underlying program has been framed as a response to alleged government “weaponization,” the court’s ruling keeps the fund on ice while the litigation proceeds and signals substantial judicial concern with how the program was created and would be administered.

Although the full contours of the ruling will matter, the immediate takeaway is straightforward: the court found enough legal risk to justify stopping the flow of money now, rather than trying to unwind grants later.

The Patent Trial and Appeal Board’s Final Written Decision in IPR2025-00230 is a useful reminder of how decisively the Board will resolve validity disputes when the petitioner’s prior-art combinations, expert support, and claim construction positions align cleanly with the intrinsic record. In this June 11, 2026 decision, the PTAB concluded the inter partes review on the merits and determined the patentability of the challenged claims under the instituted grounds.

Although each final written decision turns on the particular technology and references at issue, the structure of the Board’s analysis here follows a familiar and important pattern for practitioners.

The U.S. Supreme Court handed the Securities and Exchange Commission an important enforcement victory on June 4, upholding the agency’s authority to pursue disgorgement in securities cases. The ruling preserves a remedy the SEC has long relied on to strip alleged wrongdoers of ill-gotten gains, and it arrives at a moment when the Court has often taken a more skeptical view of federal agency power.

For the SEC, disgorgement is not just an add-on remedy.

The Justice Department has announced a $549.5 million settlement with Perfectus Aluminum Inc. and related companies to resolve allegations that they evaded customs duties on imported aluminum products by submitting false entry paperwork. The recovery stands out both for its size and for what it signals about the government’s continued willingness to use the False Claims Act as a tool in trade and customs enforcement.

According to the government, the misconduct centered on false statements and documentation affecting duties owed on aluminum imports.

The Pennsylvania Supreme Court on Monday delivered a consequential ruling for the state’s gaming industry, holding that the “skill games” that have spread through convenience stores, bars, gas stations, and other locations are slot machines under Pennsylvania law. The practical effect is significant: these machines must be limited to licensed and regulated gambling venues, rather than operating in the gray market that has fueled years of litigation and enforcement disputes.

The decision gives state regulators and law enforcement a stronger legal footing to seize or shut down machines that operators have long argued are materially different from traditional slots because they involve some degree of player skill.

A new inter partes review has been filed at the Patent Trial and Appeal Board against ResMed Corp., opening another front in the increasingly important fight over respiratory and sleep-therapy technology. The petition, docketed as IPR2026-00341 and filed June 12, 2026, places at issue the validity of a ResMed patent before the PTAB, where petitioners can seek cancellation of issued patent claims based on prior art patents and printed publications.

At this early stage, the publicly available docket information identifies the proceeding as Resmed Corp., but does not yet provide the full set of petition details typically most relevant to practitioners, including the patent number, the petitioner’s identity, and the specific prior-art combinations asserted.

The U.S. Supreme Court is set to hear a challenge involving the prolonged detention of certain noncitizens, placing renewed focus on the constitutional and statutory limits of immigration custody. The dispute arises against a backdrop of increasingly aggressive immigration enforcement and longstanding tension over how long the federal government may detain individuals without providing a meaningful bond hearing or other procedural safeguard.

At issue is not just detention policy, but the scope of executive authority in immigration administration and the role of the courts in policing that authority.

A federal judge in the Southern District of Florida has ordered additional scrutiny of the settlement resolving Donald Trump’s $10 billion lawsuit against the IRS and the Justice Department, an unusual step that puts the mechanics of government dealmaking under a brighter spotlight.

U.S. District Judge Kathleen Williams’ order follows objections from retired judges who challenged the arrangement and argued that the settlement may raise concerns about collusion, abuse of process, or other irregularities.

A new filing in View full case on Docket Alarm puts a familiar but often decisive appellate issue front and center: whether the appeal should be dismissed before merits briefing proceeds. On June 10, 2026, appellee The Legal Aid Society filed Motion No. 14 in the U.S. Court of Appeals for the Second Circuit, seeking dismissal of the appeal in docket 26-1232.

Although the docket entry itself is concise, motions to dismiss at the appellate level typically target threshold defects that can end a case without reaching the substantive issues.

The Supreme Court in early June handed the Federal Communications Commission an important administrative-law win, rejecting a challenge by ATT and Verizon to the agency’s process for imposing telecom fines. The ruling preserves a key piece of the FCC’s enforcement toolkit and, just as notably, suggests the Court is not prepared to automatically extend its recent hostility toward some forms of agency adjudication into every regulatory setting.

The dispute centered on whether the FCC’s in-house enforcement mechanism for monetary penalties runs afoul of constitutional limits that have drawn increasing scrutiny in recent years.

The Justice Department cleared Paramount’s acquisition of Warner Bros. on June 12, 2026, finding the transaction was unlikely to substantially lessen competition in traditional television markets. But the federal green light may be only the beginning. California, New York, and other states are reportedly preparing their own challenge, creating the prospect of a high-stakes showdown over how aggressively state enforcers can police deals the federal government declines to stop.

That split is what makes this story especially significant.

A sweeping federal insider-trading prosecution in Boston took a significant step forward on June 1, when 15 defendants pleaded not guilty in a case prosecutors say spanned roughly a decade and touched nearly 30 merger transactions. The U.S. Attorney’s Office in Boston has charged 30 people overall, alleging that lawyers and financial professionals improperly shared confidential deal information that was then used to trade ahead of market-moving announcements.

The case stands out both for its scale and for the professional roles allegedly involved.

Another PTAB proceeding has been filed against ResMed, with IPR2026-00341 entering the Patent Trial and Appeal Board on June 12, 2026. The petition places one of ResMed’s patents under inter partes review, opening a new front in what could become an important dispute for companies operating in the sleep-disorder and respiratory-device space.

At this stage, the publicly available docket identifies the proceeding by the title Resmed Corp., but practitioners will want to monitor the case record closely as the petition, mandatory notices, and related filings further clarify the specific patent claims at issue, the identity of all real parties in interest, and any parallel district court or ITC litigation that may shape the Board’s discretionary-review analysis.

As with any newly filed IPR, the key issues will center on which patent is being challenged, which claims are targeted, and what prior-art grounds are asserted. Typically, petitioners rely on anticipation and obviousness grounds under 35 U.S.C. §§ 102 and 103, supported by combinations of patents, printed publications, and expert declarations.

As of June 13, 2026, the legal headlines most likely to affect practice are clustering around a familiar mix: consequential court rulings, aggressive federal enforcement, and legal-system changes with downstream effects for companies and their counsel. For litigators, in-house teams, and compliance officers, the significance is less about any single headline than about what these developments signal collectively about risk, forum strategy, and enforcement priorities.

At the top of the list are recent federal court rulings that may reshape how major disputes are pleaded, defended, and appealed.

A new inter partes review proceeding at the Patent Trial and Appeal Board could draw close attention from patent owners, challengers, and counsel following the medical technology sector. In IPR2026-00341, filed June 12, 2026, the petition is styled Resmed Corp., signaling that ResMed is involved in a fresh PTAB dispute over the validity of an issued patent.

At this early stage, the public docket identifies the proceeding but may not yet fully reflect all underlying petition details, including the specific patent number, all real parties in interest, and the complete list of asserted prior-art grounds.